Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study
Purpose: This study provides a comparative survival analysis between the only two drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin, and dupilumab. Materials and methods: A multicenter, retrospective study, was performed to assess drug survival (DS) analysis by compari...
Main Authors: | Maddalena Napolitano, Maria Mariano, Antonio Cristaudo, Stefano Dastoli, Adriana Di Guida, Mario De Lucia, Gianluca Guerrasio, Steven Paul Nisticò, Maria Passante, Flavia Pigliacelli, Gabriella Fabbrocini, Cataldo Patruno |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-07-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2022.2067818 |
Similar Items
-
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01) -
Dupilumab for the treatment of adult atopic dermatitis in special populations
by: Cataldo Patruno, et al.
Published: (2022-10-01) -
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
by: Lieneke F.M. Ariëns, et al.
Published: (2019-06-01) -
Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
by: Linde deWijs, et al.
Published: (2022-12-01) -
Vitiligo during dupilumab therapy
by: Vincenzo Picone, MD, et al.
Published: (2023-06-01)